Zomedica Corp.

Equities

ZOM

CA98980M1095

Healthcare Facilities & Services

Market Closed - Nyse 04:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
0.1301 USD -0.08% Intraday chart for Zomedica Corp. +0.62% -35.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zomedica Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zomedica Seeks Acquisitions CI
Transcript : Zomedica Corp., Q4 2023 Earnings Call, Apr 01, 2024
Earnings Flash (ZOM) ZOMEDICA Posts Q4 Revenue $7.3M MT
Zomedica Corp. Reiterates Revenue Guidance for Full Year 2024 CI
Zomedica Corp. Announces Publication of Research Con Including TRUFORMA(R) Platform Is More Accurate Diagnostic Test for Feline Hyperthyroidism Than Chemiluminescent Immunoassay Platform CI
Transcript : Zomedica Corp. - Shareholder/Analyst Call
Transcript : Zomedica Corp. - Analyst/Investor Day
Zomedica Pharmaceuticals Reports Preliminary Q4 Revenue MT
Transcript : Zomedica Corp., 2023 Sales/ Trading Statement Call, Jan 17, 2024
Zomedica Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024 CI
Zomedica Corp. Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease CI
Zomedica Announces Presentation of Clinical Data in Support of New Indications for Pulsevet Shock Wave Therapy CI
Earnings Flash (ZOM) ZOMEDICA Posts Q3 Revenue $6.3M MT
Transcript : Zomedica Corp., Q3 2023 Earnings Call, Nov 13, 2023
Zomedica Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Zomedica Corp. acquired Qorvo Biotechnologies, LLC from Qorvo US, Inc. for $11.3 million. CI
Zomedica Corp. Launches its Newest Assay - Endogenous ACTH CI
Zomedica Pharmaceuticals Issued Warning From NYSE American For Failing to Meet Listing Requirement MT
Zomedica Completes Acquisition of Structured Monitoring Products MT
Earnings Flash (ZOM) ZOMEDICA Posts Q2 Revenue $6M MT
Zomedica Seeks M&A Opportunities CI
Transcript : Zomedica Corp., Q2 2023 Earnings Call, Aug 10, 2023
Zomedica Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Zomedica Corp. - Shareholder/Analyst Call
Chart Zomedica Corp.
More charts
Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ZOM Stock
  4. News Zomedica Corp.
  5. Zomedica Pharmaceuticals CFO to Retire, Replacement Appointed